M3315

MJ33 lithium salt

powder, ≥90% (NMR)

• Synonym(e): 1-Hexadecyl-3-(trifluoroethyl)-sn-glycero-2-phosphomethanol lithium
• Empirische Formel (Hill-System): C₂₂H₄₃F₃O₆PLi
• CAS-Nummer: 199106-13-3
• Molekulargewicht: 498.48
• MDL-Nummer: MFCD03787978
• UNSPSC-Code: 41106300
• PubChem Substanz-ID: 24278549
• NACRES: NA.77

Eigenschaften

• Qualitätsniveau: 100
• Assay: ≥90% (NMR)
• Form: powder
• Farbe: white to beige
• Löslichkeit: H₂O: ≥5 mg/mL (warmed at 60 °C)
• Lagertemp.: 2-8°C
• SMILES String: CCCCCCCCCCCCCCCCOCC(COCC(F)(F)F)OP(OC)([O-])=O.[Li+]
• InChI: 1S/C22H44F3O6P.Li/c1-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-29-18-21(31-32(26,27)28-2)19-30-20-22(23,24)25;/h21H,3-20H2,1-2H3,(H,26,27);/q;+1/p-1
• InChIKey: GDLMLQJISATCEL-UHFFFAOYSA-M

Beschreibung

Anwendung

MJ33 lithium salt has been used as a peroxiredoxin VI (Prdx6) inhibitor:

• to study its specific Prdx6 peroxidase activity in vitro and in breast cancer cell line (MCF-7) cell lysates[1]
• to study its effects on a mouse model of acute lung injury associated with exposure to hyperoxia[2]
• to study its potential use as a therapeutic agent[3]

Biochem./physiol. Wirkung

MJ33 acts as a non-toxic and potent inhibitor of agonist-induced activation of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase type 2 (NOX2). It also prevents lung injuries associated with lung inflammation in mice. MJ33 is a fluorinated lipid analog, which blocks the enzyme by mimicking the transition state of the substrate.[2]

Novel, active site directed, specific, competitive and reversible inhibitor of phospholipase A₂ (PLA₂).

Sicherheitshinweise

• Lagerklassenschlüssel: 11 - Combustible Solids
• WGK: WGK 3
• Flammpunkt (°F): Not applicable
• Flammpunkt (°C): Not applicable
• Persönliche Schutzausrüstung: Eyeshields, Gloves, type N95 (US)